The results of the studies reviewed above reporting the presence of GRPR/NMBRs on many medulloblastoma cell lines, coupled with the results of NMBR antagonism combined with EGFR blockade having potentiating effects reducing the viability of DAOY medulloblastoma cells (213), raise the possibility that the combination of BnR antagonists with other inhibitors of the EGFR cascade may be a novel approach worth exploring to control the growth of medulloblastomas in some patient subsets. Here, GRPR is linked to medulloblastoma.